<DOC>
	<DOCNO>NCT02856503</DOCNO>
	<brief_summary>High-doses Vitamin D ( VD ) may use target therapy breast cancer . The investigator assess effect high dose VD follow biomarkers breast cancer cell : VDR , estrogen receptor ( ER ) , progesterone receptor ( PR ) , epidermal growth factor receptor 2 ( Her2/neu ) , androgen receptor ( AR ) , well epidermal growth factor receptor 1 ( EGFR ) Ki-67 , marker proliferation , E-cadherin , marker invasion metastasis .</brief_summary>
	<brief_title>Effect High Dose Vitamin D Cancer Biomarkers Breast Cancer Tumors</brief_title>
	<detailed_description>This phase I/II open-label , non-randomized study . In phase I , fix weekly course oral high-dose Vitamin D ( VD ) plan either 3 , 4 5 week ; patient sequentially enrol 3 group ( A , B C respectively ) manner two patient may treatment-limiting toxicity ( TLTs ) . After group optimal duration VD therapy achieve `` favorable response '' determine , phase II begin enrollment . Patients must schedule surgery perform within 2- week last dose VD .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>1 . Patients must histologically confirm invasive breast carcinoma ( IBC ) high grade ( DIN3 ) Ductal Carcinoma insitu ( DCIS ) schedule primary surgery . 2 . Patients must recommended/scheduled primary surgery . 3 . Female patient 18 year age old . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . 5 . Patients must normal organ function define : Aspartate aminotransferase ( AST/SGOT ) &lt; 4 time institutional upper limit normal . Alanine transaminase ( ALT/SGPT ) &lt; 4 time institutional upper limit normal . Serum Bilirubin &lt; 1.5 mg/dl . Serum Alkaline Phosphatase &lt; 4 time institutional upper limit . Creatinine within normal institutional limit OR ; Creatinine clearance &gt; /= 60 mL/min/1.73 m^2 patient creatinine level institutional normal . Albumin within normal institutional limit 6 . Women childbearing potential ( WoCBP ) must negative ( serum urine ) pregnancy test agree use barrier contraception treatment 30days thereafter . 7 . Ability understand willingness sign write informed consent document patient legal representative . 1 . Previous history breast cancer diagnosis treatment . 2 . Synchronous bilateral breast cancer . 3 . Metastatic breast cancer 4 . Patients recommend neoadjuvant systemic therapy . 5 . Patients may receive investigational agent participate investigational drug study within 4 week precede start study treatment . 6 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 7 . Concurrent malignancy 8 . Uncontrolled hypertension 9 . Chronic cholestatic alcoholic liver disease 10 . Chronic pancreatitis 11 . Kidney impairment renal stone 12 . History parathyroidectomy 13 . Hypercalcemia , define serum level &gt; 11 mg/dl . 14 . Abnormal laboratory data : AST ( SGOT ) , ALT ( SGPT ) , Serum Bilirubin , Alkaline phosphatase , Creatinine and/or Creatinine clearance , Albumin . 15 . Patients receive medication incompatible VD . 16 . Prior know allergic reaction ( ) Vitamin D form Vitamin D. 17 . Female patient pregnant breast feeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>DCIS</keyword>
	<keyword>IBC</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Invasive Breast Carcinoma</keyword>
	<keyword>High Grade Ductal Carcinoma in-situ</keyword>
</DOC>